Pharmacoepidemiological analysis of the effect of lipid-lowering therapy on cardiovascular mortality in the regions of the Russian Federation
Open Access
- 2 August 2022
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 45-54
- https://doi.org/10.37489/2588-0519-2022-2-45-54
Abstract
Objectives. Cardiovascular diseases (CVD) are one of the leading causes of death worldwide, including Russia. According to the data obtained from the ESSE-RF study, the most common risk factor for the development of CVD is high level of cholesterol. At the same time, among drugs that lower cholesterol levels, statins are the most studied. The main aim of the study was to conduct a retrospective pharmacoepidemiological study to assess the effect of hypolipidemic therapy on overall and cardiovascular mortality in the regions of the Russian Federation. Methods. At the first stage, the indicators of population, cardiovascular and overall mortality in 2012–2018 were analyzed for 84 subjects of the Russian Federation. The time period of the analysis is determined by the timing of the implementation of the Federal project "Combating Cardiovascular Diseases". Next, we analyzed the frequency of prescribing lipid-lowering therapy in high doses in 84 regions of the Russian Federation in 2014– 2018, according to IMS Health for 2 market segments (preferential and hospital). The number of patients receiving high-dose statins (HDS) (atorvastatin 40 and 80 mg, rosuvastatin 20 and 40 mg) was calculated based on sales volumes in natural terms. Results. Based on the analysis of cardiovascular mortality, all 84 regions of the Russian Federation were divided into 3 groups: high, medium and moderate mortality. In the high-mortality group, HDS consumption per patient averaged 4.45 patients per 100,000 population, in the moderate-mortality group, 19.39 patients, and in the moderate-mortality group, 21.51 patients. Conclusions. The results of the study showed that there is a relationship between the frequency of HDS use and cardiovascular mortality in the regions of the Russian Federation. These results may indicate the effectiveness of lipid-lowering therapy in real practice.Keywords
This publication has 15 references indexed in Scilit:
- ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN THE RUSSIAN FEDERATION IN 2016Rational Pharmacotherapy in Cardiology, 2018
- DISTRIBUTION OF LIPID PROFILE VALUES IN ECONOMICALLY ACTIVE MEN AND WOMEN IN RUSSIAN FEDERATION: RESULTS OF THE ESSE-RF STUDY FOR THE YEARS 2012-2014Cardiovascular Therapy and Prevention, 2017
- Adherence to Therapy in the Outpatient Setting: the Ability to Identify and Assess the Effectiveness of TherapyKardiologiia, 2017
- Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study)Profilakticheskaya meditsina, 2016
- Cardiovascular Diseases in the Context of Russia’s Long-Term Socio-Economic Development PrioritiesAnnals of the Russian academy of medical sciences, 2015
- THE PREVALENCE OF NON-INFECTIOUS DISEASES RISK FACTORS IN RUSSIAN POPULATION IN 2012-2013 YEARS. THE RESULTS OF ECVD-RFCardiovascular Therapy and Prevention, 2014
- Blood Cholesterol Trends 2001–2011 in the United States: Analysis of 105 Million Patient RecordsPLOS ONE, 2013
- Trends in Lipids and Lipoproteins in US Adults, 1988-2010JAMA, 2012
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010